~~<i id='782827338A'><strike id='782827338A'><tt id='782827338A'><pre id='782827338A'></pre></tt></strike></i>~~

Home» focus» comprehensive

comprehensive

author：explore 2025-10-06 09:53:40 Page View：3

Hiram Secrist (left), who has Duchenne muscular dystrophy, with his mother, Kristen Secrist (center), and his grandmother, Terrie Jordan. Courtesy Secrist family

In mid-July, Kristen Secrist hopped on a call with her 5-year-old son’s doctor, who had urgent news: The first gene therapy had been approved for Duchenne muscular dystrophy. Her son, Hiram, would be a perfect candidate — if, she added, they could get him dosed in time.

The treatment was approved only for 4- and 5-year-olds. Hiram turned 6 in three weeks.

“Oh, crap,” Secrist said to herself.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： 3 questions for the future of Biden's cancer moonshot
Next article： Virginia high school admissions case could be legal follow

explore

Activists slam private health insurers over coverage restrictions

ProtestorsoutsideAmerica'sHealthInsurancePlansheadquarters.CourtesyPeople'sActionWASHINGTON—Hun

Readout Newsletter: WuXi and Congress, Boundless Bio, etc.

WinMcNamee/GettyImagesWanttostayontopofthescienceandpoliticsdrivingbiotechtoday? Signup togetourbiot

The cancer drug shortage isn’t new — and neither are the solutions

PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

A Q&A with the global head of Boehringer Ingelheim's innovation unit

MichelPairetCourtesyBoehringerIngelheimLONDON—Ataneventherelastweek,theGermanpharmaceuticalfirmBoehr